OConnell Daniel Joseph 4

What Happened

• Daniel Joseph O'Connell, CEO of Acumen Pharmaceuticals (ABOS), received equity awards on January 20, 2026: 299,800 restricted stock units (RSUs) and 450,000 derivative awards (stock options/other equity-based instrument). Both grants were reported as acquisitions (code A) with $0 cash paid at grant; combined they represent up to 749,800 potential shares subject to vesting.

Key Details

• Transaction date: 2026-01-20; Filing date: 2026-01-21 (filed the next business day).
• Reported amounts and price: 299,800 RSUs @ $0.00; 450,000 derivative awards @ $0.00.
• Shares owned after transaction: Not specified in the provided filing.
• Vesting/terms (from footnotes):
  • RSUs (F1): Each RSU converts to one share if vested. RSUs vest in three equal annual installments starting one year after the grant date, subject to continued service.
  • Derivative award (F2): The shares subject to the option vest in 48 equal monthly installments and are fully vested on the fourth anniversary of the grant, subject to continued service.
• Filing timeliness: Reported the day after the grant (within usual Form 4 timing requirements).

Context

• These are grants/awards, not open-market purchases or sales. RSUs and options are typical executive compensation to align incentives; they vest over time and only convert to shares (or are exercisable) if the vesting conditions are met. No cash value was paid at grant; market value impact depends on future stock price and vesting/exercise terms.